Latham & Watkins Advises Frontier Medicines in $67 Million Series A Financing for Development of Novel Medicines

Frontier Medicines has announced the closing of a Series A Preferred Stock financing round of $67 million led by Deerfield ManagementDroia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors, as detailed in the company’s press release. Frontier Medicines is an emerging pre-clinical stage biopharmaceutical company developing breakthrough medicines to redefine the course of debilitating diseases, starting with cancer.

Latham & Watkins LLP represented Frontier Medicines in the transaction with a Silicon Valley- based team led by partner Alan Mendelson with counsel Steven Green and associate Colin Smith. Advice was also provided on intellectual property matters by Silicon Valley partner Judith Haskowith associate Peggy Ni; and on benefits and compensation matters by Silicon Valley partner Maj Vaseghi.


Back to news